NCT06932874View on ClinicalTrials.gov

Metformin Hydrochloride Sustained-release Tablets (Ⅲ) in Patients With Type 2 Diabetes Mellitus Complicated With Coronary Heart Disease

PHASE4RecruitingINTERVENTIONAL
Enrollment

356

Participants

Timeline

Start Date

March 4, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Atherosclerotic Heart DiseaseType 2 Diabetes
Interventions
DRUG

Glucophage (Metformin Hydrochloride Tablets)

Metformin hydrochloride tablets combined with other oral hypoglycemic drugs for 24 weeks treatment.

DRUG

New sustained-release metformin tablets (Ⅲ)

The experimental group received treatment with New Metformin Sustained-release Tablets (Ⅲ) combined with other oral hypoglycemic drugs for 24 weeks.

Trial Locations (1)

100037

RECRUITING

Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
lead

China National Center for Cardiovascular Diseases

OTHER_GOV